A new clinical trial involving androgen deprivation therapy (ADT), which includes goserelin, was registered on July 28, 2026. The study, titled "Efficacy and Safety of Darolutamide Combined With Docetaxel and ADT as Neoadjuvant Therapy for Locally Advanced Prostate Cancer," is listed under identifier NCT07730151. It is designated as a Phase 2 trial. As of the listed date, the trial status is not yet recruiting. The trial is evaluating a neoadjuvant combination approach that includes darolutamide, docetaxel, and ADT for patients with locally advanced prostate cancer. No results or outcome data have been posted for this trial at this time. The registration reflects a planned study design rather than any reported efficacy or safety findings. Further details on recruitment timelines and study progress may become available as the trial status updates. Readers interested in learning more about goserelin, including its regulatory status and general background, can consult the compound overview for additional context.
Goserelin-Containing ADT Regimen Featured in New Phase 2 Trial for Prostate Cancer
See the full goserelin overview
Source: https://clinicaltrials.gov/study/NCT07730151